Unlike neoplasms of the lung, urothelial tract, and stomach where PD‐L1 expression is an FDA‐approved companion biomarker of responsiveness to anti–PD‐1 antibodies, there are no recognized or validated biomarkers in HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.